AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, i... скачать в хорошем качестве

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, i...

Dr Luis Paz-Ares speaks to ecancer about the phase 1 study of AMG 75; a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC). Initially, he explains the rationale of this study. Then Dr Paz-Ares discusses the methods and results of this study. He says that AMG 757 showed an acceptable safety profile and preliminary evidence for efficacy in patients with SCLC. The maximum tolerated dose has not been reached. Dose-finding for monotherapy is ongoing. In the end, Dr Paz-Ares talks about the future impact of this study. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php